Hyperion DeFi, Inc.

Hyperion DeFi, Inc., operates as a digital asset treasury and ophthalmic technology company in the United States. The company is a U.S. publicly listed company building a long-term strategic treasury of HYPE tokens to provide shareholders with simplified exposure to the Hyperliquid blockchain ecosystem, while also developing the Optejet ophthalmic microdose mist delivery system and related topical ocular therapies. It operates through two segments: Ophthalmic Technology and Digital Assets. The Ophthalmic Technology segment focuses on the development and planned registration of the Optejet Ocular User Filled Device, designed for horizontal, microdose spray delivery of ophthalmic liquids such as artificial tears and lens rewetting products, aiming to improve administration accuracy, patient comfort, and compliance in chronic front-of-the-eye conditions. The Digital Assets segment is engaged in acquiring, holding, and managing a reserve of HYPE and other digital assets, including on-chain activities such as validating and DeFi partnerships, staking and related treasury strategies. The company was formerly known as Eyenovia, Inc. and changed its name to Hyperion DeFi, Inc. in July 2025. Hyperion DeFi, Inc. was founded in 2014 and is based in New York, New York.